SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
ALT reported Third Quarter 2026 results. The price and volatility reaction is pending.
ALTearnings

Earnings reactions, page 3

Altimmune, Inc. (ALT) Q3 FY2026 earnings

November 12, 2026 · SharpeIQ Research Desk

Reported results

  • Cash, cash equivalents and investments totaled $480 million as of September 30, 2026.
  • Research and development (R&D) expenses were $27.0 million for the three months ended September 30, 2026.
  • General and administrative (G&A) expenses were $8.7 million for the three months ended September 30, 2026.
  • Interest income was $4.8 million for the three months ended September 30, 2026.
  • Net loss was $31.6 million, or $0.15 net loss per share, for the three months ended September 30, 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →